Cataract - Pipeline Review, H2 2013 -





Published: November 2013 | Pages: 47 | Format: PDF

Summary 

Global Markets Direct’s, 'Cataract - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cataract, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cataract. Cataract - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

Scope 

 

  • A snapshot of the global therapeutic scenario for Cataract. 
  • A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages. 
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  • Coverage of the Cataract pipeline on the basis of route of administration and molecule type. 
  • Key discontinued pipeline projects. 
  • Latest news and deals relating to the products. 

 

Reasons to buy 

 

  • Identify and understand important and diverse types of therapeutics under development for Cataract. 
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. 
  • Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

 

Table of Contents 

Table of Contents 2 

List of Tables 4 

List of Figures 4 

Introduction 5 

Global Markets Direct Report Coverage 5 

Cataract Overview 6 

Therapeutics Development 7 

An Overview of Pipeline Products for Cataract 7 

Cataract Therapeutics under Development by Companies 9 

Cataract Therapeutics under Investigation by Universities/Institutes 10 

Mid Clinical Stage Products 11 

Comparative Analysis 11 

Discovery and Pre-Clinical Stage Products 12 

Comparative Analysis 12 

Cataract Therapeutics - Products under Development by Companies 13 

Cataract Therapeutics - Products under Investigation by Universities/Institutes 14 

Companies Involved in Cataract Therapeutics Development 15 

Laboratorios Sophia S.A. de C.V. 15 

Laila Pharmaceuticals Pvt. Ltd. 16 

Cataract - Therapeutics Assessment 17 

Assessment by Monotherapy Products 17 

Assessment by Route of Administration 18 

Assessment by Molecule Type 20 

Drug Profiles 22 

dexamethasone acetate - Drug Profile 22 

Product Description 22 

Mechanism of Action 22 

R&D Progress 22 

MTP-131 - Drug Profile 24 

Product Description 24 

Mechanism of Action 24 

R&D Progress 24 

PRO-155 - Drug Profile 26 

Product Description 26 

Mechanism of Action 26 

R&D Progress 26 

caffeic acid phenethyl ester - Drug Profile 27 

Product Description 27 

Mechanism of Action 27 

R&D Progress 27 

LP-013-09 - Drug Profile 29 

Product Description 29 

Mechanism of Action 29 

R&D Progress 29 

Drug For Cataract - Drug Profile 30 

Product Description 30 

Mechanism of Action 30 

R&D Progress 30 

Cataract Therapeutics - Drug Profile Updates 31 

Cataract Therapeutics - Discontinued Products 36 

Cataract Therapeutics - Dormant Products 37 

Cataract - Product Development Milestones 38 

Featured News & Press Releases 38 

Apr 30, 2013: Omeros Ophthalmology Product OMS302 Granted Eligibility For European Centralized Review 38 

Nov 29, 2011: Omeros Submits Paediatric Investigation Plan Letter Of Intent For OMS302 To European Medicines Agency 38 

Oct 11, 2011: Omeros Announces First Patients Treated In Phase III Clinical Program Evaluating OMS302 39 

May 19, 2011: Omeros Advances OMS302 Into Phase III Clinical Development Program 40 

Mar 23, 2011: Omeros's Ophthalmology Product OMS302 Achieves Co-Primary Endpoints In Phase IIb Clinical Study 40 

Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 41 

Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 42 

Aug 23, 2010: InSite Vision Initiates Phase I/II Clinical Study Of ISV-303 For Post-Surgical Ocular Pain And Swelling 43 

Jul 27, 2010: Omeros Initiates Phase IIb Clinical Trial For OMS302 In Patients Undergoing Cataract Surgery 44 

Jan 05, 2010: Icon Bioscience Initiates Phase II/III Pivotal Clinical Study Of Novel Ophthalmic Drug Candidate IBI-10090 44 

Appendix 46 

Methodology 46 

Coverage 46 

Secondary Research 46 

Primary Research 46 

Expert Panel Validation 46 

Contact Us 47 

Disclaimer 47 

 

List of Tables 

Number of Products Under Development for Cataract, H2 2013 7 

Products under Development for Cataract - Comparative Analysis, H2 2013 8 

Number of Products under Development by Companies, H2 2013 9 

Number of Products under Investigation by Universities/Institutes, H2 2013 10 

Comparative Analysis by Mid Clinical Stage Development, H2 2013 11 

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12 

Products under Development by Companies, H2 2013 13 

Products under Investigation by Universities/Institutes, H2 2013 14 

Laboratorios Sophia S.A. de C.V., H2 2013 15 

Laila Pharmaceuticals Pvt. Ltd., H2 2013 16 

Assessment by Monotherapy Products, H2 2013 17 

Assessment by Stage and Route of Administration, H2 2013 19 

Assessment by Stage and Molecule Type, H2 2013 21 

Cataract Therapeutics - Drug Profile Updates 31 

Cataract Therapeutics - Discontinued Products 36 

Cataract Therapeutics - Dormant Products 37 

 

List of Figures 

Number of Products under Development for Cataract, H2 2013 7 

Products under Development for Cataract - Comparative Analysis, H2 2013 8 

Products under Development by Companies, H2 2013 9 

Products under Investigation by Universities/Institutes, H2 2013 10 

Mid Clinical Stage Products, H2 2013 11 

Discovery and Pre-Clinical Stage Products, H2 2013 12 

Assessment by Monotherapy Products, H2 2013 17 

Assessment by Route of Administration, H2 2013 18 

Assessment by Stage and Route of Administration, H2 2013 19 

Assessment by Molecule Type, H2 2013 20 

Assessment by Stage and Molecule Type, H2 2013 21 

 

Companies Mentioned  

Laboratorios Sophia S.A. de C.V. 

Laila Pharmaceuticals Pvt. Ltd.